March 7, 2018 / 12:45 PM / 2 months ago

BRIEF-Esperion Therapeutics Says Bempedoic Acid Observed To Be Safe & Well-Tolerated In Phase 3 Study

March 7 (Reuters) - Esperion Therapeutics Inc:

* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST PIVOTAL PHASE 3 STUDY OF BEMPEDOIC ACID

* ESPERION THERAPEUTICS SAYS PHASE 3 STUDY OF BEMPEDOIC ACID MET PRIMARY ENDPOINT WITH 28% LOW DENSITY LIPOPROTEIN CHOLESTEROL LOWERING

* ESPERION THERAPEUTICS SAYS BEMPEDOIC ACID OBSERVED TO BE SAFE AND WELL-TOLERATED IN THE PHASE 3 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below